217 related articles for article (PubMed ID: 22450349)
41. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Lenders N; McCormack A
Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
[TBL] [Abstract][Full Text] [Related]
42. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.
Nishioka H; Inoshita N
Brain Tumor Pathol; 2018 Apr; 35(2):57-61. PubMed ID: 29318396
[TBL] [Abstract][Full Text] [Related]
43. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
[TBL] [Abstract][Full Text] [Related]
44. Newer Concepts in the Classification of Pituitary Adenomas.
Sathyakumar R; Chacko G
Neurol India; 2020; 68(Supplement):S7-S12. PubMed ID: 32611886
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic implications of accurate classification of pituitary adenomas.
Mete O; Asa SL
Semin Diagn Pathol; 2013 Aug; 30(3):158-64. PubMed ID: 24144285
[TBL] [Abstract][Full Text] [Related]
46. Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series.
Padovan M; Cerretti G; Caccese M; Barbot M; Bergo E; Occhi G; Scaroni C; Lombardi G; Ceccato F
Expert Rev Endocrinol Metab; 2023 Mar; 18(2):181-198. PubMed ID: 36876325
[TBL] [Abstract][Full Text] [Related]
47. [The problem of pituitary adenoma classification: contribution of ultrastructure].
Racadot J; Olivier L; Vila-Porcile E; Peillon F
Rev Otoneuroophtalmol; 1974; 46(3):215-22. PubMed ID: 4445659
[No Abstract] [Full Text] [Related]
48. Ectopic ACTH-secreting pituitary adenoma of the sphenoid sinus: case report of endoscopic endonasal resection and systematic review of the literature.
Seltzer J; Lucas J; Commins D; Lerner O; Lerner A; Carmichael JD; Zada G
Neurosurg Focus; 2015 Feb; 38(2):E10. PubMed ID: 25639312
[TBL] [Abstract][Full Text] [Related]
49. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
Gilis-Januszewska A; Wilusz M; Pantofliński J; Turek-Jabrocka R; Sokołowski G; Sowa-Staszczak A; Kluczyński Ł; Pach D; Zieliński G; Hubalewska-Dydejczyk A
Endokrynol Pol; 2018; 69(3):306-312. PubMed ID: 29319131
[TBL] [Abstract][Full Text] [Related]
50. HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy.
Kun Z; Yuling Y; Dongchun W; Bingbing X; Xiaoli L; Bin X
Technol Cancer Res Treat; 2016 Dec; 15(6):NP95-NP104. PubMed ID: 26647409
[TBL] [Abstract][Full Text] [Related]
51. Clinically Silent Adrenocorticotropic Hormone-Positive Crooke Cell Adenoma: Case Report and Review of Literature.
Todnem N; Ward A; Segar S; Rojiani AM; Rahimi SY
World Neurosurg; 2018 Nov; 119():197-200. PubMed ID: 30077745
[TBL] [Abstract][Full Text] [Related]
52. Sarcomatous change after sellar irradiation in a growth hormone-secreting pituitary adenoma.
Prabhu SS; Aldape KD; Gagel RF; Benjamin RS; Trent JC; McCutcheon IE
Can J Neurol Sci; 2003 Nov; 30(4):378-83. PubMed ID: 14672272
[TBL] [Abstract][Full Text] [Related]
53. Von Hippel-Lindau disease and aggressive GH-PRL pituitary adenoma in a young boy.
Tudorancea A; François P; Trouillas J; Cottier JP; Girard JJ; Jan M; Gilbert-Dussardier B; Richard S; Lecomte P
Ann Endocrinol (Paris); 2012 Feb; 73(1):37-42. PubMed ID: 22265326
[TBL] [Abstract][Full Text] [Related]
54. Pathology of pituitary tumors.
Kovacs K; Horvath E
Endocrinol Metab Clin North Am; 1987 Sep; 16(3):529-51. PubMed ID: 3319594
[TBL] [Abstract][Full Text] [Related]
55. Refractory nonfunctioning pituitary adenomas.
Kolitz T; Greenman Y
Pituitary; 2023 Jun; 26(3):278-280. PubMed ID: 36786972
[TBL] [Abstract][Full Text] [Related]
56. [Classification, pathology and molecular biology of pituitary adenoma].
Tapar K; Kovach K; Khorvat E
Arkh Patol; 1997; 59(3):7-17. PubMed ID: 9290033
[TBL] [Abstract][Full Text] [Related]
57. Ganglion cell containing pituitary adenomas: signs of neuronal differentiation in adenoma cells.
Kontogeorgos G; Mourouti G; Kyrodimou E; Liapi-Avgeri G; Parasi E
Acta Neuropathol; 2006 Jul; 112(1):21-8. PubMed ID: 16699777
[TBL] [Abstract][Full Text] [Related]
58. Aggressive pituitary adenomas--diagnosis and emerging treatments.
Di Ieva A; Rotondo F; Syro LV; Cusimano MD; Kovacs K
Nat Rev Endocrinol; 2014 Jul; 10(7):423-35. PubMed ID: 24821329
[TBL] [Abstract][Full Text] [Related]
59. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Kovacs K; Horvath E; Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE
Hum Pathol; 2007 Jan; 38(1):185-9. PubMed ID: 17056093
[TBL] [Abstract][Full Text] [Related]
60. Amyloid in pituitary adenomas.
Voigt C; Saeger W; Gerigk C; Lüdecke DK
Pathol Res Pract; 1988 Sep; 183(5):555-7. PubMed ID: 3237543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
